Boston Life Science Market Overview





Market Observations

Market indicators are still muddled, suggesting Greater Boston's life science market continues to search for a bottom.

The reopening of the IPO window led six local biotech companies to go public in 2024. Post initial offering performance has struggled though.

Over the past year, "Big Pharma" invested more in mergers and acquisitions than in 2022 and 2023 combined.



While tenant demand appears to have stabilized, underlying weakness persists as several users require additional funding to transact.

Tenants seeking built-out space have their pick from available spec suites, subleases and secondgeneration spaces.

Pricing is correcting, with asking rents declining by 2.2% over the quarter across the metro, lease rates are down 10.7% from the peak.

With more than 9.0 million SF of new supply coming online in the past 12 months, 2024 represents a historic high for deliveries.



Greater Boston venture capital funding increased by nearly 47.0% during the second half of 2024, bringing annual volumes to \$7.5 billion.

Liquidity is slowly returning to the laboratory market, but values are off significantly from the peak and investors remain cautious.

1. Economy

- 2. Leasing Market Fundamentals
- 3. Submarket Overviews


4Q24

Economy



Impacts of Layoffs and Future Workforce Development

Greater Boston's unemployment rate is rising, reaching 3.6% in November, the highest level since 2022. Despite ongoing layoffs, the region's unemployment rate remains below the national average, suggesting a degree of resilience within the local economy, as businesses continue to adapt and seek talent in emerging sectors like AI, clean tech, etc.




Source: Moody's Analytics, Boston-Cambridge-Newton, MA-NH MSA

Local Employers Maintain A More Bullish Outlook

Sentiment among Massachusetts business leaders reached a two-year high during the fourth quarter of 2024. Continued economic expansion and expectations for investment support following the U.S. federal election were two key reasons for improving optimism late in the year. A potential softening in the labor markets could dampen this recent improvement in business confidence.






Source: AIM Board of Economic Advisors

Local Labor Market Conditions Remain Sluggish

Openings for life science-related occupations in the Boston metro area are still below peak levels and employment within the local research and development segment continues to trail the U.S. average.



Source: Moody's Analytics, JobsEQ, Newmark Research













4Q24


Leasing Market Fundamentals



Laboratory Fundamentals Are Still Searching For A Bottom

As record levels of new supply delivers throughout Greater Boston, laboratory users now have more options available to them than ever before. This is especially true for "built-out" space, which includes spec suites, sublease offerings and second-generation space. Despite year-over-year growth in leasing velocity and diminishing supply risk, fundamentals will remain challenged as the market works through an immense supply-demand imbalance.





Source: Newmark Research

			40%		
		34.1%	35%		
			30%		
			250/	te	
			25%	Total Vacancy Rate	
			20%	acanc	
				tal Va	
			15%	To	
		44.40/			
		11.1%	10%		
			5%		
			00/		
23	202	24	0%		






Underlying Laboratory Demand Remains Challenged

Leasing velocity slowed considerably during the fourth quarter of 2024, with roughly 2.1 million SF of leases executed during the past 12 months. While this represents a 26.1% increase from 2023, much of this activity was driven by key renewals and extensions, which accounted for more than half of the total square feet transacted in 2024. Tenant demand appears to have stabilized around 2.0 million SF; however, many requirements are waiting for on funding to move forward and true demand is much lower.





Leasing Activity is Improving, but Renewals Are Still Prevalent

Following a sluggish first half of 2024, leasing velocity improved during the third quarter of 2024. Vertex Pharmaceuticals executed the largest transaction of the year—a renewal of its office and laboratory operations in Boston's Seaport. Newly-constructed 66 Galen St. in Watertown landed two anchor tenants during the third guarter of 2024, which brings the building's occupancy up to roughly 50%. Tenants' continued hesitancy to make real estate commitments will weigh on the market's leasing recovery, however,


Notable 4Q24 Lease Transaction	ons				
Tenant	Building(s)	Submarket	Туре	Square Feet	
Ultragenyx Pharmaceutical, Inc.	19 Presidential Way, Woburn	Route 128 - North	Lease Extension	40,060	
The large pharma company extended	d their lease in Woburn.				
Verastem, Inc.	117 Kendrick Street, Needham	Route 128 - West	Lease Extension	27,810	
The biopharma company executed a	n extension on their Needham location.				
Flare Therapeutics, Inc.	400 Technology Square, Cambridge	East Cambridge	Direct Lease	21,621	
The early-stage biotech company se	cures a sizeable presence in Cambridge.				
Rubix Life Sciences	4 Kingsbury, Watertown	Urban Edge – West	Direct Lease	16,000	
The biotech R&D company moves in	to new space in Watertown, coming in from Lawrer	nce.			
TreeFrog Therapeutics, Inc.	99 Erie Street, Cambridge	Mid Cambridge	Direct Lease	13,488	
This biotech company secures its US	S Headquarters in Mid Cambridge.				
TriNetX	100 CambridgePark Drive, Cambridge	West Cambridge	Direct Lease	9,119	
The life science data company move	s into a new Cambridge location.				





Laboratory Rents Continued to Slide Through Year-End

Pricing for laboratory space in Greater Boston is off 10.7% from the peak due to weaker market fundamentals. User-centric market conditions will persist due to supply-side pressures, and tenants will maintain negotiating power. New construction may keep lease rates elevated, but expectations are for further price reductions in the coming quarters.



Source: Newmark Research













4Q24

Submarket Overviews



















For more information:

Liz Berthelette Head of Northeast Boston Research elizabeth.berthelette@nmrk.com Michael Roberts Senior Research Analyst Boston Research michael.roberts@nmrk.com Hailey Roche Research Analyst Boston Research hailey.roche@nmrk.com

E. Da Moura Research Analyst Boston Research

edmilson.damoura@nmrk.com

Boston

225 Franklin Street Boston, MA 02110 t 617-863-8090 *bostonresearch@nmrk.com*

New York Headquarters 125 Park Avenue New York, NY 10017 t 212-372-2000

nmrk.com

Newmark has implemented a proprietary database and our tracking methodology has been revised. With this expansion and refinement in our data, there may be adjustments in historical statistics including availability, asking rents, absorption and effective rents. Newmark Research Reports are available at <u>nmrk.com/insights</u>.

All information contained in this publication (other than that published by Newmark) is derived from third party sources. Newmark (i) has not independently verified the accuracy or completeness of any such information, (ii) does not make any warranties or representations, express or implied, concerning the same and (iii) does not assume any liability or responsibility for errors, mistakes or inaccuracies of any such information set forth in this publication (i) may include certain forward-looking statements, and there can be no guarantee that they will come to pass, (ii) is not intended to, nor does it contain sufficient information, to make any recommendations or decisions in relation to the information set forth therein and (iii) does not constitute or form part of, and should not be construed as, an offer to sell, or a solicitation of any offer to buy, or any recommendation with respect to, any securities. Any decisions made by recipient should be based on recipient's own independent verification of any information set forth in this publication or any of the information it contains with any third party. This publication is for informational purposes only and none of the content is intended to advise or otherwise recommend a specific strategy. It is not to be relied upon in any way to predict market movement, investment in securities, transactions, investment strategies or any other matter. If you received this publication by mistake, please reply to this message and follow with its deletion, so that Newmark can ensure such a mistake does not occur in the future.

